Mark H. Sherman, MDCM, FRCPc, Diplomate American Board of Clinical Lipidology
Associate Professor, Department of Medicine
Tel: 514-934-1934 ext. 35090
mark.sherman [at] mcgill.ca
I graduated Medicine from McGill University in 1987, followed by Internal Medicine residency and Chief Medical Residency at the Jewish General Hospital (Montreal) and Endocrinology at McGill University. I did an apprenticeship in the Lipid Clinic at the Royal Victoria Hospital (MUHC) and have since 1993 been its director. I have been director of the Metabolic Day Centre at the MUHC since 2008, and was interim director of Endocrinology and Metabolism from 2012 through 2016. I am Royal College certified in Internal Medicine and Endocrinology, and National Lipid Association (NLA) certified as a diplomate of the American Board of Clinical Lipidology.
Dyslipidemia, diabetes, hypercholesterolemia, hypertriglyceridemia
Research or Clinical Activities
Most of my time is spent as a clinician. I see patients for all endocrine disorders; notably diabetes and thyroid disorders, but my major focus is in the MUHC Lipid Clinics, which I direct. Being a clinician allows me to see fascinating clinical cases. A substantial amount of my time also goes into clinical teaching in Lipid and Endocrinology clinics and the in-patient consultation service and at McGill University to first year medical students. I am currently involved as PI or co-PI in a number of clinical trials with lipid-lowering and anti-diabetic agents. I am also investigating some of the advanced lipid effects of bariatric surgery, and I collaborate with colleagues in Cardiology, Clinical Epidemiology, Pneumology and Hepatology on lipid and metabolic studies.
1. Dasgupta K, Rosenberg E, Joseph L, Trudeau L, Bacon SL, Chan D, Sherman M, Rabasa-Lhoret R, Daskalopoulou SS for the SMARTER trial group.
Physician step prescription and monitoring to improve ARTERial health (SMARTER).
(Oral Presentation Abstract (Dr Dasgupta) Diabetes Canada Meeting, Edmonton, AB, Nov 1-4, 2017); Canadian Journal of Diabetes (41, Supplement 1) S10, October 2017
2. Robert-Halabi M, Ni J, Nguyen A, Dube M-P, Al Turki A, Sherman M, Thanassoulis G, Gregoire J, Tardif J-C, Huynh T.
Long-Term Residual Risk and Predictors of Cardiovascular Disease in Individuals Taking Statins for Primary Prevention: Insights from the Cartagene Study.
Journal of the American College of Cardiology, 2019, 73(9):1773. doi: 10.1016/S0735-1097(19)32379-4
3. Al Turki A, Marafi M, Dawas A, Dube M-P, Vieira L, Sherman MH, Gregoire J, Thanassoulis G, Tardif J-C, Huynh T.
Meta-Analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes
American Journal of Cardiology, 2019, 124 (12), 1869-1875 https://doi.org/10.1016/j.amjcard.2019.09.011
4. Boutet C, Lopez Laporte M, Alturki A, Ni J, Tardif J, Dube M, GregoireJ, Sherman M, Ferreira J, Thanassoulis G, Sharma A, Huynh T.
Contemporary Risk Factors For Cardiovascular Outcomes Among Men And Women - Insights From The Cartagene Study.
Canadian Journal of Cardiology, 2020, 36(10) Supplement, S18. https://doi.org/10.1016/j.cjca.2020.07.054
5. Tromp T, Hartgers M, Hovingh G, Vallejo-Vaz A, Ray K, Soran H, Freiberger T, Bertolini S, Harada-Shiba M, Blom D, Raal F, Cuchel M, and the Homozygous Familial Hypercholesterolemia International Clinical Collaborators.
Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)
Lancet, Published online January 28, 2022 https://doi.org/10.1016/S0140-6736(21)02001-8